Envoy Medical (COCH) Competitors

Envoy Medical (NASDAQ:COCH) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.

Do analysts prefer COCH or LUNG?

Envoy Medical presently has a consensus price target of $9.25, indicating a potential upside of 542.36%. Pulmonx has a consensus price target of $11.53, indicating a potential upside of 267.04%. Given Envoy Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Envoy Medical is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pulmonx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63

Does the MarketBeat Community believe in COCH or LUNG?

Pulmonx received 30 more outperform votes than Envoy Medical when rated by MarketBeat users. However, 100.00% of users gave Envoy Medical an outperform vote while only 46.99% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Envoy Medical	Outperform Votes 9 100.00%	Underperform Votes No Votes
Pulmonx	Outperform Votes 39 46.99%	Underperform Votes 44 53.01%

Does the media prefer COCH or LUNG?

In the previous week, Pulmonx had 2 more articles in the media than Envoy Medical. MarketBeat recorded 5 mentions for Pulmonx and 3 mentions for Envoy Medical. Pulmonx's average media sentiment score of 1.03 beat Envoy Medical's score of 0.22 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envoy Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmonx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals believe in COCH or LUNG?

8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 58.9% of Envoy Medical shares are owned by company insiders. Comparatively, 6.8% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has preferable earnings & valuation, COCH or LUNG?

Envoy Medical has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$212K	144.86	-$29.91M	-$1.38	-1.04
Pulmonx	$87.47M	1.45	-$60.84M	-$1.44	-2.18

Which has more volatility and risk, COCH or LUNG?

Envoy Medical has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.

Is COCH or LUNG more profitable?

Pulmonx has a net margin of -67.31% compared to Envoy Medical's net margin of -7,607.55%. Envoy Medical's return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-7,607.55%	N/A	-262.28%
Pulmonx	-67.31%	-55.36%	-33.53%

Summary

Envoy Medical beats Pulmonx on 10 of the 18 factors compared between the two stocks.